Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy.
Tomonori Hirashima
No relevant relationships to disclose
Koichi Azuma
No relevant relationships to disclose
Nobuyuki Yamamoto
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Chugai Pharma
Toshiaki Takahashi
No relevant relationships to disclose
Makoto Nishio
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer; Taiho Pharmaceutical
Taizo Hirata
No relevant relationships to disclose
Kaoru Kubota
No relevant relationships to disclose
Kazuo Kasahara
No relevant relationships to disclose
Toyoaki Hida
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma; Kyowa Hakko Kirin
Hiroshige Yoshioka
Honoraria - Chugai Pharma
Kohei Suzuki
Employment or Leadership Position - Kyowa Hakko Kirin
Shiro Akinaga
Employment or Leadership Position - Kyowa Hakko Kirin
Kazuto Nishio
No relevant relationships to disclose
Tetsuya Mitsudomi
Consultant or Advisory Role - Chugai Pharma; Kyowa Hakko Kirin; Roche
Kazuhiko Nakagawa
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma